Apparent autoinduction of valproate beta-oxidation in humans

Area of Science:

• Pharmacology
• Drug Metabolism
• Clinical Pharmacology

Background:

• Valproate (VPA) is an antiepileptic drug with a complex metabolic profile.
• Understanding VPA autoinduction is crucial for optimizing therapeutic use and managing potential drug interactions.
• The beta-oxidation pathway is a significant route for VPA metabolism in humans.

Purpose of the Study:

• To investigate whether chronic oral dosing of sodium valproate (NaVPA) induces auto-metabolism along its beta-oxidation pathway in healthy human volunteers.
• To quantify changes in VPA and its metabolite levels and formation clearances over a three-week dosing period.

Main Methods:

• Twelve healthy young volunteers received oral NaVPA (200 mg twice daily) for three weeks.
• Serial blood and urine samples were collected on days 7 and 21 to analyze VPA and its metabolites.
• Pharmacokinetic parameters, including plasma area under the curve (AUC) and formation clearances, were calculated.

Main Results:

• Plasma AUC(0,12h) of VPA was significantly lower on day 21 compared to day 7, suggesting increased VPA clearance.
• Formation clearances of VPA to urinary E-2-en-VPA and 3-oxo-VPA (beta-oxidation metabolites) significantly increased from day 7 to day 21.
• No significant differences in formation clearances were observed for VPA-glucuronide or 4-OH-VPA.

Conclusions:

• Regular low-dose VPA intake over three weeks is associated with a modest induction of VPA metabolism via the beta-oxidation pathway.
• Metabolism of VPA through glucuronidation or 4-hydroxylation pathways does not appear to be significantly induced by chronic low-dose VPA.
• These findings contribute to a better understanding of VPA pharmacokinetics and the potential for autoinduction in clinical practice.